Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocuronium vs Cisatracurium in Chronic Kidney Disease
NCT07203287Phase 4
Key facts
- Status
- Recruiting
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Countries
- 1
- Sponsor
- The University of Texas Medical Branch at Galveston
- Modality
- Small Molecules
- Conditions
- neuromuscular blockade (NMB)
01
Overview
Phase 4, randomised trial in neuromuscular blockade (NMB) comparing Rocuronium and Sugammadex (RS) Group with Cisatracurium and Neostigmine (CN) Group (2 arms). Primary endpoint: Post Operative Pulmonary Complications at 7 days. Started Aug 2025; status: recruiting.
02
Design
2 arms- Study design
- Randomized
Rocuronium and Sugammadex (RS) Group
Given rocuronium and sugammadex as part of standard regimen
Cisatracurium and Neostigmine (CN) Group
Given cisatracurium and neostigmine as part of standard regimen
03
Who it enrols
Adults aged 18-80 with chronic kidney disease requiring surgery with general anesthesia, endotracheal intubation, and neuromuscular blockade. Excludes patients with end-stage renal disease, those requiring dialysis, pregnant women, and those undergoing urgent/emergent procedures or renal transplantation.
04
Endpoints
Primary
Post Operative Pulmonary Complications
Secondary
Hospital Length of Stay
Post Anesthesia Care Unit length of stay
Number of patients with cardiac instability
Beyond the preview
Go deeper on NCT07203287.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07203287.